91 terminated. 91 Phase 1, 35 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 91 | Terminated 91 |
| Phase 2 | 35 | Terminated 35 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas BI 765049 - Colorectal Carcinoma, Gastric Carcinoma | Phase 1 | Terminated | Boehringer Ingelheim | 14 | 2025-03-28 | 2026-10-27 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. 68Ga-FF58, 177Lu-FF58 - Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 24 | 2023-10-06 | 2025-12-24 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 EO-3021, Ramucirumab (CYRAMZA®), Dostarlimab - Stomach Neoplasm, Gastrointestinal Neoplasms | Phase 1 | Terminated | Elevation Oncology | 88 | 2023-08-10 | 2025-11-14 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours [225]-FPI-2059, [111In]-FPI-2058 - Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck | Phase 1 | Terminated | 3B Pharmaceuticals GmbH | 19 | 2023-02-07 | 2025-08-24 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors NC410, pembrolizumab - Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 97 | 2022-10-06 | 2026-08-13 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Bemarituzumab, CAPOX, SOX - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 72 | 2022-05-17 | 2026-07-29 |
| A Study of SGN-ALPV in Advanced Solid Tumors SGN-ALPV - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Terminated | Seagen Inc. | 43 | 2022-04-21 | 2025-02-10 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab - Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fusion Pharmaceuticals Inc. | 6 | 2022-04-20 | 2023-12-19 |
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 1 | 2022-04-14 | 2024-12-12 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors PF-07265028, Sasanlimab - Advanced Solid Tumors, Gastric Cancer | Phase 1 | Terminated | Pfizer | 21 | 2022-02-24 | 2026-02-19 |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers SBT6050, trastuzumab deruxtecan, tucatinib - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 / Phase 2 | Terminated | Silverback Therapeutics | 2 | 2022-02-08 | 2022-08-18 |
Showing 20 of 91. Sign in to see all of them.
Stomach Neoplasms (87) · Carcinoma, Non-Small-Cell Lung (31) · Colorectal Neoplasms (28) · Esophageal Neoplasms (28) · Breast Neoplasms (24) · Ovarian Neoplasms (23) · Squamous Cell Carcinoma of Head and Neck (18) · Endometrial Neoplasms (16) · Melanoma (16) · Neoplasms (16) · Neoplasm Metastasis (15) · Pancreatic Neoplasms (15) · Carcinoma, Renal Cell (14) · Lung Neoplasms (13) · Triple Negative Breast Neoplasms (13)
Digestive System Diseases (91) · Gastrointestinal Diseases (91) · Neoplasms by Site (87) · Digestive System Neoplasms (85) · Gastrointestinal Neoplasms (83) · Neoplasms (73) · Neoplasms by Histologic Type (50) · Neoplasms, Glandular and Epithelial (45) · Urogenital Diseases (44) · Urogenital Neoplasms (44) · Female Urogenital Diseases (42) · Female Urogenital Diseases and Pregnancy Complications (42) · Carcinoma (41) · Skin Diseases (41)
pembrolizumab (15) · Capecitabine (6) · Trastuzumab (6) · Cyclophosphamide (5) · Docetaxel (5) · Cisplatin (4) · Fluorouracil (4) · Irinotecan (4) · aldesleukin (4) · Carboplatin (3) · Gemcitabine (3) · Leucovorin (3) · Nivolumab (3) · Oxaliplatin (3) · fludarabine (3)
Pfizer (5) · National Cancer Institute (NCI) (4) · Seagen Inc. (4) · Amgen (2) · AstraZeneca (2) · Merck Sharp & Dohme LLC (2) · NextCure, Inc. (2) · 3B Pharmaceuticals GmbH (1) · ADC Therapeutics S.A. (1) · AHS Cancer Control Alberta (1) · AIDS Malignancy Consortium (1) · AbGenomics B.V Taiwan Branch (1) · AbbVie (1) · Actym Therapeutics, Inc. (1) · Aminex Therapeutics, Inc. (1)
United States (70) · Spain (14) · United Kingdom (13) · France (11) · South Korea (11) · Australia (10) · Canada (10) · Italy (8) · Japan (8) · Taiwan (8) · Belgium (5) · China (5) · Germany (4) · Netherlands (4) · Poland (3)
Suzanne McGoldrick, MD (2) · Aaron Enke (1) · Adrian Kilcoyne, MD (1) · Akhil Kumar, MD (1) · Alan Tan, MD (1) · Amit Mahipal, M.D. (1) · Andreas Kaubisch (1) · Andres Forero-Torres, MD (1) · Andrew Ko, MD (1) · Anna Dorothea Wagner, MD (1) · Bao Rui, Doctor (1) · Becker Hewes, MD (1)
PMID 19738454, PMID 28576557, PMID 31802410, PMID 32819975, PMID 34951522, PMID 35176457, PMID 35247086, PMID 35429391, PMID 37860278, PMID 38441850, PMID 40445839, PMID 41724817, PMID 42259602, PMID 42705861
2019 (3), 2017 (2), 2018 (2), 2014 (1), 2015 (1), 2023 (1), N01CM62204 (1), P30CA008748 (1), P30CA014520 (1), R01CA082661 (1), U01CA062491 (1), U01CA069856 (1), U01CA121947 (1), U10CA032102 (1)